ArticleHeliyon2024
Green synthesis of copper ions nanoparticles functionalized with rhamnolipid as potential antibacterial agent for pathogenic bacteria.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Synergistic antimicrobial effect of novel heterophase Cu/CuZn/ZnO nanoparticles.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Article
- Chitosan hydrogels loaded with CuScientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper-based nanoparticles possess broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria, making them a cost-effective alternative to other metal-based nanoparticles. The development of eco-friendly copper based nanopaticles using biodegradable and non-toxic biosurfactants, such as rhamnolipid is being explored in this study. In the present study, Cu(I)-rhamnolipid nanoparticles (Cu(I)-Rl Nps) was prepared by coprecipitation method. The structural analysis by using FTIR and XRD techniques revealed that Cu(I)-Rl Nps was successfully produced, as indicated by the detectable of ionic and covalent-coordinations bond between rhamnolipid and Cu(I) ions. Further analysis using TEM, PSA and ZPA suggest that the resulted Cu(I)-Rl Nps have spherical shape with the diameter range of 141.7-536.3 nm and the surface charge of -30 mV, respectively. The antibacterial activity of Cu(I)-Rl Nps surpassed that of the copper-based nanoparticles, free-state Cu(I) ions and rhamnolipid, which was determined by MIC/MBC methods. The Cu(I)-Rl Nps inhibition to the growth of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.